Health Catalyst, Inc. (NASDAQ:HCAT) General Counsel Sells $18,800.00 in Stock

Health Catalyst, Inc. (NASDAQ:HCAT) General Counsel Benjamin Landry sold 2,500 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $7.52, for a total transaction of $18,800.00. Following the sale, the general counsel now owns 72,250 shares in the company, valued at $543,320. This represents a 3.34 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Benjamin Landry also recently made the following trade(s):

• On Friday, December 6th, Benjamin Landry sold 19,268 shares of Health Catalyst stock. The stock was sold at an average price of $8.32, for a total value of $160,309.76.

Health Catalyst Stock Down 6.4 %

Shares of NASDAQ:HCAT opened at $6.89 on Friday. The business has a fifty day simple moving average of $7.79 and a 200 day simple moving average of $7.52. Health Catalyst, Inc. has a 12-month low of $5.42 and a 12-month high of $11.41. The firm has a market cap of $419.24 million, a P/E ratio of -5.10 and a beta of 1.36. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The company had revenue of $76.40 million during the quarter, compared to analyst estimates of $76.27 million. Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. Health Catalyst’s revenue was up 3.5% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.22) earnings per share. Analysts predict that Health Catalyst, Inc. will post -0.33 earnings per share for the current year.

Institutional Investors Weigh In On Health Catalyst

Several large investors have recently modified their holdings of the company. First Light Asset Management LLC lifted its holdings in Health Catalyst by 438.5% in the second quarter. First Light Asset Management LLC now owns 3,956,089 shares of the company’s stock valued at $25,279,000 after buying an additional 3,221,408 shares during the period. Millennium Management LLC lifted its stake in shares of Health Catalyst by 96.3% in the 2nd quarter. Millennium Management LLC now owns 2,413,280 shares of the company’s stock valued at $15,421,000 after purchasing an additional 1,184,131 shares during the period. Nepsis Inc. boosted its position in shares of Health Catalyst by 67.9% during the 3rd quarter. Nepsis Inc. now owns 2,104,528 shares of the company’s stock valued at $17,131,000 after purchasing an additional 851,448 shares in the last quarter. Fred Alger Management LLC acquired a new stake in Health Catalyst during the third quarter worth approximately $6,858,000. Finally, Portolan Capital Management LLC bought a new stake in Health Catalyst in the third quarter worth approximately $5,402,000. 85.00% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Evercore ISI upped their price objective on Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 8th. Stephens raised their price target on shares of Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a research note on Thursday, November 14th. Cantor Fitzgerald reiterated an “overweight” rating and set a $16.00 price objective on shares of Health Catalyst in a research report on Friday, October 4th. Royal Bank of Canada increased their price objective on shares of Health Catalyst from $8.00 to $9.00 and gave the company a “sector perform” rating in a research note on Thursday, November 7th. Finally, Piper Sandler reiterated an “overweight” rating and set a $12.00 price target (up from $11.00) on shares of Health Catalyst in a report on Tuesday, November 26th. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $11.45.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.